Enovis Co. (NYSE:ENOV) Shares Purchased by Victory Capital Management Inc.

Victory Capital Management Inc. raised its holdings in shares of Enovis Co. (NYSE:ENOV) by 14.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,846 shares of the company’s stock after acquiring an additional 4,099 shares during the period. Victory Capital Management Inc. owned approximately 0.06% of Enovis worth $1,414,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Ridgewood Investments LLC bought a new position in shares of Enovis in the second quarter valued at approximately $44,000. DekaBank Deutsche Girozentrale bought a new position in Enovis during the 3rd quarter valued at $55,000. Innealta Capital LLC acquired a new position in shares of Enovis during the 2nd quarter valued at $65,000. Benjamin F. Edwards & Company Inc. raised its stake in shares of Enovis by 28.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock worth $76,000 after buying an additional 371 shares in the last quarter. Finally, Heritage Family Offices LLP acquired a new stake in shares of Enovis in the third quarter valued at $206,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $65.00 target price on shares of Enovis in a report on Thursday, November 7th. Evercore ISI lowered their price objective on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 1st. JPMorgan Chase & Co. cut their target price on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. Finally, JMP Securities assumed coverage on shares of Enovis in a report on Thursday, October 3rd. They set an “outperform” rating and a $62.00 target price for the company. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $67.00.

Enovis Stock Up 3.4 %

ENOV stock opened at $48.27 on Tuesday. The company’s 50 day simple moving average is $42.70 and its 200-day simple moving average is $44.92. Enovis Co. has a 52-week low of $38.27 and a 52-week high of $65.03. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The firm has a market capitalization of $2.70 billion, a P/E ratio of -21.84 and a beta of 1.91.

Enovis (NYSE:ENOV) last released its earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.11. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The company had revenue of $505.22 million during the quarter, compared to analyst estimates of $504.44 million. During the same quarter in the prior year, the company earned $0.56 earnings per share. The company’s revenue for the quarter was up 21.0% on a year-over-year basis. As a group, equities research analysts anticipate that Enovis Co. will post 2.79 EPS for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.